51
Participants
Start Date
October 1, 2024
Primary Completion Date
October 1, 2025
Study Completion Date
October 1, 2026
Fluzoparib
The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
Apatinib Mesylate
The study treatment was followed by a 3-week treatment cycle. First day of each dosing cycle, subjects are also required to complete various examinations, including vital signs, physical examination, laboratory examination, physical status score, and BMD testing to evaluate the safety and tolerability of continued treatment.
Anhui Provincial Hospital
OTHER_GOV